Background-Lower vitamin B 6 concentrations are reported to confer an increased and independent risk for cardiovascular disease (CVD). The mechanism underlying this relationship, however, remains to be defined. Other diseases, such as rheumatoid arthritis, are associated with reduced vitamin B 6 levels. Despite a clear distinction in pathophysiology, inflammatory reaction may be the major link between these diseases. We hypothesized a relationship between pyridoxal 5Ј-phosphate (PLP), the active form of vitamin B 6 , and the marker of inflammation C-reactive protein (CRP). We also evaluated whether total plasma homocysteine (tHcy), a well-defined risk factor for CVD and a major determinant of plasma PLP levels, had a possible role as a mediator of this hypothesized relationship. Methods and Results-Data from 891 participants from the population-based Framingham Heart Study cohort were analyzed. Subjects were divided into 2 groups according to normal or elevated CRP values: group 1, CRP Ͻ6 mg/L; group 2, CRP Ն6 mg/L. Plasma PLP levels were substantially lower in group 2 than in group 1 (mean values in group 2, 36.5 nmol/L versus 55.8 nmol/L in group 1, PϽ0.001). In a multiple logistic regression model adjusted for tHcy, the association of PLP with CRP remained highly significant (Pϭ0.003). 
P yridoxal 5Ј-phosphate (PLP), the active form of vitamin B 6 , participates in a wide range of reactions, including metabolism of homocysteine, a sulfur-containing amino acid that is thought to be a risk factor for occlusive vascular disease. 1, 2 Recent studies have shown that plasma PLP levels are significantly reduced in certain pathological conditions. An association with low plasma PLP levels has been demonstrated in patients with rheumatoid arthritis (RA), 3 and lower concentrations of this coenzyme have been reported to be an independent risk factor for cardiovascular disease (CVD). 4, 5 Because plasma PLP is an important determinant of plasma total homocysteine (tHcy), an interpretation for a role of this coenzyme has been addressed primarily through its link with homocysteine metabolism. Nevertheless, the relationship between low PLP and diseases cannot be fully explained on the basis of an abnormal tHcy metabolism. 5, 6 Since the first description by Rinehart and Greenberg of arteriosclerotic lesions in pyridoxine-deficient monkeys, 7 other mechanisms, related or unrelated to the homocysteine pathway, have been proposed for a role of vitamin B 6 in vascular tissue damage. Vitamin B 6 deficiency has been associated with impairment of enzymes involved in determining the structural integrity of the arterial wall, 8 in altering platelet function, 9 and in interfering with cholesterol metabolism. 10 Nonetheless, no conclusive mechanism has been identified thus far. An alternative explanation is that the low PLP levels observed in these diseases are linked to inflammatory processes. 6 As for RA, its chronic inflammatory nature is clearly recognized. There is also growing evidence suggesting that inflammation plays a key part in the pathogenesis of atherosclerosis. 11 Indeed, there is an increasing body of evidence supporting the hypothesis that atherosclerosis shares many similarities with RA, a typical chronic inflammatory disease. 12,13 C-reactive protein (CRP), one of the major acute-phase reactants, as well as cytokines regulating its plasma levels (eg, interleukin-6), have been used to predict the risk of cardiovascular events. 14 Furthermore, it was recently demonstrated that CRP induces adhesion molecule expression in human endothelial cells, supporting the hypothesis of a direct role for CRP in promoting an inflammatory component in the atherosclerotic process. 15 In patients with RA, low plasma PLP levels have been found to be associated also with erythrocyte sedimentation rate and levels of the inflammatory cytokine tumor necrosis factor-␣. 3 More evidence for an inverse correlation between PLP and indices of acute-phase reaction, such as plasma ␣ 1 -antichymotrypsin, copper, and blood leukocyte count, was also recently described in a sample of elderly subjects. 16 To evaluate the relationship between plasma PLP, the inflammation marker CRP, and tHcy, we analyzed data available from the 20th examination of the Framingham Heart Study, a well-characterized, population-based cohort.
Methods

Study Population
The study sample consisted of the survivors from the original Framingham Heart Study cohort, an epidemiological study established in Framingham, Mass, during the period 1948 through 1950. 17 The original cohort consisted of 5209 subjects of both sexes 30 to 62 years old. The surviving members of this cohort have been examined every 2 years, and in 1988 and 1989, 1402 survivors participated in the 20th examination. Institutional review boards approved the study, and all patients gave informed consent. Characteristics of the study population have been described in detail elsewhere. 18 Additional covariables assessed for the present analyses were age, sex, cigarette smoking, diabetes, history of coronary artery disease, history of CVD, history of stroke events, and history of hypertension. Detailed operational definitions for all these covariables are provided elsewhere. 19, 20 
Laboratory Testing
Samples of venous blood were drawn from each subject to determine the concentration of CRP, tHcy, folate, vitamin B 12 , and PLP. tHcy was determined by high-performance liquid chromatography with fluorimetric detection. 21 Plasma folate was measured by a microbial assay (Lactobacillus casei) in a 96-well plate. 22 Plasma PLP was assayed by the tyrosine decarboxylase apoenzyme method. 23 Plasma vitamin B 12 was measured with a (Magic) radioimmunoassay kit from Ciba-Corning. Serum CRP was determined by an immunoturbidimetric assay (SPQ antibody reagent set II, DiaSorin). Creatinine levels were measured in nonfasting plasma by the Jaffe method, adapted for autoanalyzers. Dietary vitamin B 6 intake was estimated from diet records by use of a semiquantitative food-frequency questionnaire. 24 
Statistical Analysis
The statistical analyses were confined to a subset of 891 subjects for whom a complete set of CRP, vitamin, and tHcy values was available. To evaluate the relationships among plasma PLP, tHcy, and CRP, we divided the population into 2 groups according to CRP values: group 1, CRP Ͻ6 mg/L, ie, within the range of normality (nϭ834, 93.6%); group 2, CRP Ն6 mg/L, ie, increased levels (nϭ57, 6.4%). Distributions of continuous variables were expressed as meanϮSD. Logarithmic transformation was performed on all skewed variables to normalize their distributions. Therefore, geometric means (antilogarithms of the transformed means) are presented for tHcy, folate, PLP, vitamin B 12 , creatinine, albumin, and dietary vitamin B 6 intake. Ninety-five percent CIs for the geometric means were calculated by use of the transformed values, and these intervals are displayed as the antilogarithm of the transformed data. Adjustment for confounding variables (sex, age, smoking, albumin, and creatinine) was performed by general linear model analysis (specifically, ANCOVA) for plasma folate, plasma PLP, vitamin B 12 , plasma tHcy, albumin, and dietary vitamin B 6 intake. Statistical significance refers to a value of PϽ0.05. All the statistical computations were performed with an SAS PROC GLM program (SAS user's guide, version 8.0, SAS Institute, 1999).
Results
The relevant characteristics of the study sample divided according to CRP values, ie, group 1, CRP Ͻ6 mg/L and group 2, CRP Ն6 mg/L, are shown in Table 1 . As indicated, the 2 groups did not differ with respect to age, sex, plasma folate, vitamin B 12 , dietary vitamin B 6 intake, and creatinine levels. Neither were they significantly different in terms of clinical characteristics, such as prevalence of hypertension (group 1, 58.6%; group 2, 67.4%, Pϭ0.191), diabetes (group 1, 14.3%; group 2, 13.7%, PϾ0.2), CVD (group 1, 33.8%; group 2, 36.8%, PϾ0.2), and coronary heart disease (group 1, 20.4%; group 2, 17.5%, PϾ0.2). There was a higher prevalence of stroke occurrence in group 2 (12.3%) than in group 1 (6.2%); however, the difference was not statistically significant (Pϭ0.08). Nonsmokers were 88.9% of the population sample, and the cumulative percentage of subjects smoking Ͻ10 cigarettes/d was 91.6% (data not shown). Plasma PLP was significantly lower in the group with abnormal CRP values than in the other group (PϽ0.001). Serum albumin was significantly lower in group 2 than in group 1 (PϽ0.001). Nevertheless, the difference in albumin concentration between the 2 groups ranged within the reference intervals and did not match the greater difference in PLP concentration. The 2 groups did also differ in tHcy levels, but the difference did not reach statistical significance (Pϭ0.063). To evaluate a possible role for tHcy in the relationship between PLP and CRP values, we performed a general linear model analysis. Values are expressed as meanϮSD or as indicated. Folate, PLP, vitamin B 12 , tHcy, creatinine, and vitamin B 6 intake data are presented as geometric means (antilogarithms of the transformed means), and 95% CIs are reported in parentheses with 2-tailed P values.
*Plasma folate levels were available for 888 subjects (group 1, nϭ831; group 2, nϭ57).
†Vitamin B 12 levels were available for 876 subjects (group 1, nϭ820; group 2, nϭ56).
‡Vitamin B 6 intake was available for 714 subjects (group 1, nϭ675; group 2, nϭ39).
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As shown in Table 2 , the strong association of PLP with CRP remained highly significant even after adjustment for tHcy (PϽ0.001). Conversely, after adjustment for PLP concentrations, the relationship between CRP and tHcy became clearly not statistically significant (Pϭ0.571).
Discussion
These data demonstrate a strong association between decreased plasma PLP and increased levels of CRP, a major systemic marker of inflammation. Moreover, the association of PLP with CRP remained highly significant even after adjustment for tHcy, which is known to be an important metabolic indicator of vitamin B 6 status as well as a cardiovascular risk factor. Furthermore, the low vitamin B 6 levels were not attributable to impaired dietary intake, because it was similar in the 2 groups. In a recent study, we also found a negative correlation between PLP and erythrocyte sedimentation rate, disease activity status, disease-related pain, joint swelling, and stiffness in patients with RA (E.-P. Chiang, PhD, et al, unpublished data, 2000). These results were consistent with data from similar studies. 3 Furthermore, we demonstrated that the low PLP levels were not due to diminished vitamin B 6 intake, nor were they associated with increased urinary excretion of 4-pyridoxic acid, an end product of vitamin B 6 catabolism.
Despite the lack of a pathophysiological explanation for an association between PLP and markers of acute-phase status, a plausible interpretation of our data is that PLP is acting as a coenzyme for the inflammation-related functions. Because vitamin B 6 is integrally involved in the synthesis of nucleic acids and consequently in mRNA and protein synthesis, the production of cytokines and other polypeptide mediators during the inflammatory response might require an increased utilization of this coenzyme. This model is consistent with the observation that vitamin B 6 deficiency is associated with impairment in differentiation and maturation of monocytederived macrophages and T lymphocytes, inflammatory cells whose activation leads to the release of several enzymes and cytokines. 25 Vitamin B 6 deficiency was also reported to alter the regulation of interleukin-2 production. 26 The present study, moreover, confirms observations from others of a lack of association of increased CRP and tHcy levels, 27, 28 suggesting that the relationship between tHcy and atherosclerosis cannot be explained through a link with CRP per se, whereas both are independent risk factors for CVD.
Various conditions such as renal failure, smoking, and age are known to be associated with reduced levels of PLP. In addition, PLP, the predominant form of plasma vitamin B 6 , is primarily bound to albumin, whose diminished levels may result in lower values of circulating PLP. Adjustment for albumin, creatinine, age, sex, and smoking, however, did not affect the observed association.
Indeed, additional studies are necessary to clarify whether inflammation-associated decreases in circulating PLP play a role in the cascade of metabolic events related to certain diseases. PLP is one of the most important coenzymes in maintaining the balance between protein synthesis and degradation. Therefore, it is likely that low levels of PLP may reflect a higher utilization of the coenzyme in an underlying inflammatory process, rather than a defective intake or excessive vitamin B 6 catabolism. The low circulating PLP seen as a possible indicator of an inflammatory status as well as a major determinant of tHcy levels may further our understanding of the mechanisms by which this metabolite acts as a risk factor for CVD. Values are expressed as geometric means (antilogarithms of the transformed means), and 95% CIs are reported in parentheses with 2-tailed P values.
